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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizWe report the case of a 24-year old female with a seizure
disorder and previously undiagnosed long QT syndrome whose
QT interval increased and developed into torsades de pointes after
her levetiracetam dose was increased. The patient had been having
seizures since age 10. The episodes typically occurred in the early
morning and witnesses describe shaking of her entire body,
incontinence, and while the patient was not aware of the events
at the time when they occurred, she did get tired and confused
after the events. She had been started on carbamazepine as a child,
with escalating doses as she aged.
She presented to the NorthShore epilepsy clinic for the ﬁrst
time after a generalized seizure, and was started on levetiracetam
250 mg twice a day with the plan of increasing the dose over weeks
then weaning her carbamazepine (initial random carbamazepine
level was 10.1 mg/ml). A brain MRI showed minimal T2 hyper-
intensities in white matter which were interpreted as non-speciﬁc.
Her EEG showed intermittent right temporal sharp waves with an
electrophysiological maximum at T4 and occasional right temporal
polymorphic theta-range slowing suggestive of mild focal cerebral
dysfunction. While seizures have not been captured on EEG, the
combination of her clinical presentation and focal abnormalities on* Corresponding author. Tel.: +1 847 570 2570; fax: +1 847 570 2073.
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her serum levetiracetam level was 8.1 mg/ml, and an ECG showed
a QTc of 520 ms (Fig. 1A). She was referred to cardiology for
evaluation of her prolonged QT interval. Eleven days later she
presented to an outside hospital after a generalized seizure; 3 days
before presentation her twice daily levetiracetam had been
increased to 500 mg. At that visit to the ED her levetiracetam
dose was increased to 1000 mg twice a day and she was discharged
home.
The following day she presented to the NorthShore ED with
complaints of ‘‘difﬁculty breathing.’’ Initial ECG showed normal
sinus rhythm with a QTc of 771 ms (Fig. 1B). Her levetiracetam
level was 34 mg/ml and carbamazepine level was 8.1 mg/ml. While
in the ED her mental status deteriorated and her heart rhythm
changed into polymorphic ventricular tachycardia/torsades de
pointes. She was treated with a lidocaine drip which had almost no
effect, and intravenous magnesium sulfate was more effective at
terminating the rhythm, but the rhythm recurred, requiring
multiple cardioversions. The patient also developed sustained
monomorphic ventricular tachycardia of varying morphologies
that appeared to initiate with PVCs suggestive of early after
depolarizations (Fig. 1C). Because of concerns of recurrent
hemodynamic collapse she was intubated and sedated; a
continuous infusion of magnesium sulfate was used to control
her ventricular arrhythmias and her anti-epileptics were discon-
tinued. The day after presentation her QTc decreased to 670 ms
with a levetiracetam level of 2.7 mg/ml and carbamazepine level ofserved.
Fig. 1. Evolution of cardiac rhythm. (A) ECG 12 days before the index admission
showed normal sinus rhythm at 58 bpm and QTc of 520 ms; serum levetiracetam
was 8.1 mg/ml. (B) First ECG on the day of admission showed normal sinus rhythm
at 81 bpm and QTc of 771 ms; serum levetiracetam 34 mg/ml. (C) ECG late on the
day of admission showed monomorphic ventricular tachycardia at 145 bpm.
Fig. 2. QTc and levetiracetam concentration. The time course of change in QTc (black
diamonds) is plotted with respect to torsades de pointes on day 0. Levetiracetam
was increased to 1000 mg twice a day on day-1. Levetiracetam concentration is
shown with open squares; the ﬁnal levetiracetam measurement was made on day 3
(asterisk) and was below the detection limit represented by the dashed line. The
points labeled with 1A and 1B were QTc intervals calculated from the ECGs shown
in Fig. 1(A) and (B), respectively.
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undetectable (carbamazepine was 2.1 mg/ml the following day,
then became undetectable) with lower QT intervals (Fig. 2). Her
hospitalization was complicated by pneumonia and diabetes
insipidus but she was successfully extubated and the following
week a dual-chamber deﬁbrillator device was implanted. She
recovered to her baseline, and in the 2-year follow up period her
seizures have been well controlled on clobazam with no further
episodes of ventricular tachyarrhythmia.
As part of the patient’s work up for long QT interval, a point
mutation was identiﬁed in the KCNH2 potassium channel
(Met645Ile). KCNH2 is a delayed rectiﬁer channel involved in
cardiac repolarization, and mutations in KCHN2 are associatedwith the LQT2 syndrome that can present with both long QT
intervals and seizures [1].
The prolongation of QT interval after increasing the levetir-
acetam dose was unexpected since levetiracetam has been one of
the AEDs thought to have a minimal effect on QT intervals.
Siniscalchi and coworkers reported an increase of only about 25 ms
in QTc in post-stroke patients treated with levetiracetam [2]. These
patients had adult-acquired seizure disorders and are presumed
to have had wild-type ion channels.
Levetiracetam has multiple proposed mechanisms of action,
among them is inhibition of Kv3.1 that like KCNH2 is a delayed-
rectiﬁer potassium channel. Unlike KCNH2, however, Kv3.1 is
widely expressed in brain tissue, is not thought to play a signiﬁcant
role in cardiac conduction, and has different gating kinetics than
KCNH2 [3]. As a result, it is unknown if levetiracetam would affect
either wild-type or mutant KCNH2 channels. Other AEDs do inhibit
KCNH2, with phenytoin, phenobarbital, and lamotrigine having the
most signiﬁcant effect [4]. Carbamazepine, which this patient was
also taking, has been shown to inhibit KCNH2, but with a high IC50/
unbound therapeutic concentration making it unlikely to be
clinically relevant [4], and the dose of carbamazepine had not
been changed in the preceding year. This case raises the possibility
that levetiracetam has an unanticipated effect on cardiac conduc-
tion in patients with KCNH2 mutations, especially when used in
combination with other AEDs.
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